Bellevue Group AG Has $12.53 Million Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

Bellevue Group AG reduced its position in Evolent Health, Inc. (NYSE:EVH) by 58.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,113,658 shares of the technology company’s stock after selling 1,556,392 shares during the period. Bellevue Group AG owned about 0.96% of Evolent Health worth $12,529,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health in the fourth quarter valued at approximately $26,000. R Squared Ltd acquired a new stake in Evolent Health during the 4th quarter valued at $31,000. AlphaQuest LLC lifted its holdings in Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after purchasing an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Evolent Health in the fourth quarter valued at $61,000.

Evolent Health Stock Performance

Shares of NYSE:EVH opened at $10.73 on Friday. The company’s 50 day simple moving average is $9.48 and its 200 day simple moving average is $12.01. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.09 and a beta of 1.20.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. As a group, research analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In other news, CEO Seth Blackley acquired 55,225 shares of Evolent Health stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the transaction, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at approximately $6,867,575.17. The trade was a 7.81 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Daniel Joseph Mccarthy bought 11,040 shares of the stock in a transaction on Thursday, March 6th. The stock was purchased at an average cost of $9.01 per share, with a total value of $99,470.40. Following the acquisition, the president now owns 389,004 shares in the company, valued at approximately $3,504,926.04. This represents a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 74,000 shares of company stock worth $666,315. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $13.00 target price on shares of Evolent Health in a report on Monday, April 28th. Citigroup decreased their target price on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Piper Sandler reissued an “overweight” rating and set a $16.00 price target (down from $17.00) on shares of Evolent Health in a report on Friday, February 21st. JPMorgan Chase & Co. lowered their price objective on Evolent Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Monday, March 10th. Finally, Truist Financial reduced their target price on shares of Evolent Health from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $17.71.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.